Anastrozol 1 mg

• Anastrozole 1 mg
• Brand: Magnus Pharmaceuticals
• Content: 30 tablets | 1 mg per tablet
• Manufactured in: Europe

Product Overview

Anastrozole 1 mg is a third-generation non-steroidal aromatase inhibitor (AI) designed to suppress peripheral estrogen synthesis via competitive inhibition of the CYP19 enzyme. Widely used in endocrine and oncology research, it allows for precise estrogen-reduction modeling, testosterone-to-estradiol (T:E) modulation, and post-cycle therapy simulations.

Its long half-life (~46–50 hours) supports once-daily dosing, and the film-coated tablets offer logistical advantages over injectables in hormone-regulation studies. With high selectivity and oral bioavailability, anastrozole is a key tool in studies of male hypogonadism, fertility, and body recomposition protocols.

Key Research Highlights

• Selective aromatase blockade: Inhibits CYP19 to suppress peripheral estrogen by 80% in vivo [DrugBank, NCBI]
• Extended half-life: Elimination t 46–50 hours supports consistent once-daily sampling [PubChem, Wikipedia]
• T:E ratio modulation:1 mg/day improved testosterone-to-estradiol ratios and semen metrics in male trials [PMC]
• Body recomposition support: Reduced systemic estrogen helps prevent gynecomastia and sustain lean-mass retention [Verywell Health]
• Room-temperature stability: Film-coated tablets store safely 25°C — no cold-chain required [Mayo Clinic]

Suggested Laboratory Applications

Aromatase inhibition and estrogen-suppression studies

Post-cycle therapy and hormonal recovery research

T:E ratio modulation in hypogonadal or fertility trials

Anti-estrogen support in anabolic-steroid modeling

Oncology research in estrogen-dependent tumors

Technical Specifications

Detection Window

Medium-to-long (varies with dose and sampling)

Documented Benefits

estrogen >80%, T:E ratio, recurrence of ER+ breast cancer

Main Risks

Arthralgia, hot-flushes, lipid shifts, bone-density reduction

Total Active Compound

30 mg per carton (1 mg 30 tablets)

Shelf-life

36 months (manufacturer specification)

PubChem-Supported Research Insights

Suppresses peripheral estrogen synthesis by over 80%

Increases T: E ratio in hypogonadal males and fertility models

Demonstrated efficacy in reducing recurrence of estrogen-dependent cancers

Supports lean tissue retention and gynecomastia control

Extended half-life allows single daily dosing for consistent hormonal regulation

Documented Research Side Effects

Joint pain, bone mineral density reduction, hot-flushes

Altered lipid profiles ( HDL, LDL) in chronic use

Cardiovascular strain risk with long-term administration

Insomnia and mood shifts in estrogen-sensitive models

Handling & Compliance

For Research Use Only — Not for human or veterinary useStore at 15–25°C, protect from moisture and lightPurchase confirms qualified researcher statusListed on WADA Prohibited List S4 — any exposure may result in a positive anti-doping test